BioMarin Pharmaceutical logo

BioMarin Pharmaceutical

BMRN | NASDAQ
Chart Builder DCF Calculator
$57.99
+$0.76 (+1.33%)
At close: Nov 16, 2026, 4:00 PM ET
$57.99
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET
+1.33%

No price chart data available for 1D timeframe.

Rating

Updated: Nov 14, 2026
31.4
+1.5 pts
Fundamentals Weak
Market Sentiment Neutral
Moat Narrow
Sector Rank #754/1021 (Top 74%)

Key Statistics

Market Data

Market Cap $11.23B
1D Range
57.11 58.84
52W Range
49.67 70.24

Valuation (TTM)

PE -724.88
PB 1.80
EV/EBITDA 32.95

Valuation (NTM)

Forward PE 18.89
Forward PEG -17.17
Price Target $90.00
Loading financial charts...

Profile

BioMarin Pharmaceutical Inc. specializes in creating and bringing to market treatments for individuals suffering from severe and often fatal rare disorders and other critical medical conditions. The c...

Sector Healthcare
Industry Biotechnology
Employees 3,221
IPO Date Jul 26, 1999
Fiscal Year January - December

Latest News

BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms

17 hours ago · marketbeat.com

BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript

18 hours ago · seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript
BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline

5 days ago · marketbeat.com

BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript

5 days ago · seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions

13 days ago · seekingalpha.com

BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
BioMarin to Participate in Upcoming Investor Conferences

13 days ago · prnewswire.com

BioMarin to Participate in Upcoming Investor Conferences
BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript

14 days ago · seekingalpha.com

BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript
BioMarin Pharmaceutical Q3 Earnings Call Highlights

14 days ago · marketbeat.com

BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

14 days ago · zacks.com

BioMarin (BMRN) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates

14 days ago · zacks.com

BioMarin Pharmaceutical (BMRN) Q3 Earnings Surpass Estimates

Earnings

Latest Earnings
Nov 2, 2026
EPS
$0.23
Beat +566.25%
REV
$1.02B
Beat +0.21%
Next Earnings
Feb 22, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
21
Consensus
Buy
Price Target
$90.00
Upside
+55.20%
Buy (17)
Hold (4)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.